# Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz

*Источник: BioBuzz*
*Дата: 2026-09-16*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5" target="_blank">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color="#6f6f6f">BioBuzz</font>

[Оригинал](https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/)